Advertisement
Screener

XERIS BIOPHARMA HOLDINGS, INC. (XERS) Graph

XERS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $92.10M; Cost of revenue (m); Research and development $10.67M; Selling, general and administrative $61.03M.
  • 2026-03-31: Revenue $83.13M; Cost of revenue (m); Research and development $8.78M; Selling, general and administrative $53.14M.
  • 2025-12-31: Revenue $85.81M*; Cost of revenue (m); Research and development $7.87M*; Selling, general and administrative $47.50M*.
  • 2025-09-30: Revenue $74.38M; Cost of revenue (m); Research and development $7.48M; Selling, general and administrative $46.46M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

XERS revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$91.00MGvoke$22.55MKeveyis$11.68MProduct Other$0.00Recorlev$56.78MRoyalty ContractAnd Other Revenue$1.10MRevenue$92.10MOperating income$5.17MOther income, net-$36.27MResearch & development$10.67MSelling, general& administrative$61.04MIncome tax$0.00Net income-$31.10M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$92.10M(m)$10.67M$61.03M(m)$0.00-$31.10M
2026-03-31$83.13M(m)$8.78M$53.14M(m)$0.00$2.23M
2025-12-31$85.81M*(m)$7.87M*$47.50M*(m)$0.00*$11.08M*
2025-09-30$74.38M(m)$7.48M$46.46M(m)$0.00$621.00K
2025-06-30$71.54M(m)$8.05M$44.39M(m)$0.00-$1.93M
2025-03-31$60.12M(m)$7.75M$44.02M(m)$0.00-$9.22M
2024-09-30$54.27M(m)$5.89M$44.97M(m)-$3.32M-$15.74M
2024-06-30$48.06M(m)$5.76M$39.99M(m)$749.00K-$15.01M
2024-03-31$40.64M(m)$7.82M$38.38M(m)$307.00K-$18.98M
2023-09-30$48.32M(m)$5.03M$37.29M(m)-$338.00K-$12.19M
2023-06-30$38.01M(m)$6.09M$37.63M(m)-$675.00K-$19.84M
2023-03-31$33.20M(m)$4.84M$33.60M(m)$0.00-$16.83M
2022-09-30$29.73M(m)$6.04M$34.49M(m)-$339.00K-$21.83M
2022-06-30$25.31M(m)$3.72M$32.98M(m)-$339.00K-$26.18M
2022-03-31$22.07M(m)$6.25M$35.91M(m)-$408.00K-$33.71M
2021-09-30$11.06M$3.22M$5.66M$26.54M$32.20M$0.00-$26.01M
2021-06-30$8.91M(m)$5.38M$25.93M(m)$0.00-$27.52M
2021-03-31(m)(m)$4.03M$19.08M(m)$0.00-$18.41M
2020-09-30$9.40M$2.83M$3.88M$16.48M$20.36M$0.00-$16.00M
2020-06-30(m)(m)(m)(m)(m)(m)-$24.10M
2020-03-31(m)(m)(m)(m)(m)(m)-$29.18M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeIncome taxNet income
2026-06-30$175.23M$19.45M$114.18M$0.00-$28.87M
2025-06-30$131.66M$15.81M$88.41M$0.00-$11.15M
2024-06-30$88.70M$13.58M$78.37M$1.06M-$33.98M
2023-06-30$71.20M$10.93M$71.24M-$675.00K-$36.68M
2022-06-30$47.38M$9.97M$68.90M-$747.00K-$59.90M
2021-06-30$17.10M$9.41M$45.00M$0.00-$45.93M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30$206.04M(m)$23.29M$134.87M(m)$0.00-$10.53M
2024-09-30$142.97M(m)$19.47M$123.34M(m)-$2.27M-$49.72M
2023-09-30$119.52M(m)$15.96M$108.53M(m)-$1.01M-$48.87M
2022-09-30$77.10M(m)$16.01M$103.39M(m)-$1.09M-$81.73M
2021-09-30$28.16M$8.43M$15.08M$71.54M$86.62M$0.00-$71.94M
2020-09-30$13.07M$5.92M$15.81M$55.73M$71.55M-$110.00K-$69.28M

Revenue and expense 12 month

Period endRevenueResearch and developmentSelling, general and administrativeIncome taxNet income
2025-12-31$291.85M$31.16M$182.37M$0.00$554.00K
2024-12-31$203.07M$25.56M$163.48M-$2.27M-$54.84M
2023-12-31$163.91M$22.34M$146.09M-$1.25M-$62.26M
2022-12-31$110.25M$20.97M$137.75M-$1.42M-$94.66M
2021-12-31$49.59M$25.16M$125.72M$0.00-$122.72M
2020-12-31(m)$20.92M$73.73M-$110.00K-$91.14M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Innoviva, Inc. (INVA)United States$1.493B4.62
Xencor Inc (XNCR)United States$1.776B-7.33
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Septerna, Inc. (SEPN)United States$1.783B-63.01